Regarding the insulin analogs that BIOD is working on, BIOD tested almost 100 different formulations applying their proprietary technology to a major pharma's insulin analog before deciding on 10 to be evaluated further in a diabetic swine model. Of these 10, BIOD believes it has 3 that are potential candidate formulations to move forward into trials (they showed slides with the presentation showing the PK/PD benefit of their version of the analog compared to the analog alone). Discussions are underway with the potential pharma partner and they expect to have a decision in 4Q this year of the analogs and/or RHI (BIOD-105 and BIOD-107) that will move forward (and presumably whether or not they will be doing that alone or in conjunction with the potential big pharma partner).
Market Data 
Markets 
AI
